Welcome to our dedicated page for Finch Therapeutics Group news (Ticker: FNCH), a resource for investors and traders seeking the latest updates and insights on Finch Therapeutics Group stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Finch Therapeutics Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Finch Therapeutics Group's position in the market.
Finch Therapeutics Group announced that CEO Mark Smith, PhD, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 2:45 PM ET. The event will be available via a live webcast on Finch's website, with a replay accessible for 30 days post-event.
Finch focuses on microbiome therapeutics, including its lead candidate, CP101, which targets recurrent C. difficile infections and has received FDA designations for expedited development. The company is also advancing treatments for chronic hepatitis B and autism spectrum disorder.
Finch Therapeutics Group, Inc. (Nasdaq: FNCH) announced the appointment of Susan E. Graf as Chair of the Audit Committee of its Board of Directors. Graf brings over 25 years of biopharma experience, including a strong background in corporate strategy, finance, and M&A. Following Finch's recent IPO and positive Phase 2 data for its lead candidate, CP101, Graf expressed enthusiasm about joining during this pivotal time. Finch is advancing programs in chronic hepatitis B and autism, alongside its ongoing development of CP101 for recurrent C. difficile infection, which has received FDA designations.
On April 15, 2021, Finch Therapeutics (Nasdaq: FNCH) announced that CEO Mark Smith, PhD, will participate in the Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. The event includes a fireside chat and panel discussion, with a recording available on the Finch website post-event. Finch is a clinical-stage company specializing in microbiome therapeutics, notably its lead candidate CP101 for recurrent C. difficile infections, which is in late-stage trials. CP101 has received Breakthrough Therapy and Fast Track designations from the FDA.
Finch Therapeutics Group, Inc. (Nasdaq: FNCH) announced an upsized initial public offering of 7,500,000 shares at $17.00 per share, expecting gross proceeds of $127.5 million. The offering is set to close on March 23, 2021. Finch has granted underwriters a 30-day option for 1,125,000 additional shares. The company’s shares will begin trading on the Nasdaq on March 19, 2021. Finch is focused on microbiome therapeutics and is advancing CP101 for recurrent C. difficile infection, alongside other candidates for different medical needs.